In Radiology, AI Is Blurring the Line Between Technology Development and Clinical Practice
OVERVIEWA new wave of radiology practices are aggressively embracing AI by developing and deploying tools in-house, marketing themselves as "AI-native" practices. This trend is blurring regulatory and operational lines between technology development and clinical care delivery. These AI-native radiology startups argue that owning both the practice and the AI development creates advantages: tighter feedback loops, faster iteration, and better alignment between tools and clinical workflows. However, the model raises questions about regulatory oversight, patient safety, and whether these practices should be subject to medical device regulations. The phenomenon reflects a broader healthcare trend where the distinction between "software as a service" and "medical device" becomes increasingly ambiguous when the same organization develops, validates, and deploys AI tools in clinical settings. Regulators have not yet clarified whether these in-house deployments require the same scrutiny as commercial medical devices. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.